Portfolio Companies News
July 5, 2022Nordic Nanovector to Discontinue PA...
Oslo, Norway, 5 July 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL). Following a comprehensive review and i... read more
June 28, 2022Bulletin from the Annual General Me...
Stockholm, Sweden – June 28, 2022 – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Tuesday, 28 June 2022. At the Annual General Meeting, the following principal resolutions were passed. The presented annual report was adopted, and the members of the Board of Director... read more
June 23, 2022CHMP issues a positive opinion reco...
STOCKHOLM — June 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the European Medicines Agency´s (EMA) Committee for Medicinal Products f... read more
June 23, 2022Fusion Pharmaceuticals Announces FD...
HAMILTON, ON and BOSTON, June 23, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA... read more
June 23, 2022Targovax announces that the FDA has...
The US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) Application for the combination of TG01 and QS-21 STIMULON™The IND is a major milestone for the TG mutant RAS program, and represents the first time that a TG vaccine is authorized for clinical trials in the ... read more
May 16, 2022Q1 2022 General Market Overview
October 07, 2021HealthCap strengthens senior team
November 29, 2021HealthCap’s 25th company anniversary!
Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.
46 of the portfolio companies have been taken public on fourteen different markets.
31 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.